With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products... Show more
NVO is expected to report earnings to fall 26.02% to 76 cents per share on November 04
Q3'26
Est.
$0.77
Q1'26
Missed
by $0.05
Q4'25
Beat
by $0.10
Q3'25
Missed
by $0.09
Q2'25
Est.
$0.93
The last earnings report on May 06 showed earnings per share of $1.04, missing the estimate of $1.09. With 11.03M shares outstanding, the current market capitalization sits at 189.74B.